Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab.

Abstract	We describe one report of a cervical dysplasia in a patient receiving natalizumab for multiple sclerosis. Other cases were identified in the WHO's global individual case safety report database, VigiBase® . These data underline the importance of monitoring HPV infection in patients with MS treated with natalizumab.
Authors	Geneviève Durrieu, Quentin Dardonville, Michel Clanet, Jean-Louis Montastruc
Journal	Fundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 33 Issue 1 Pg. 125-126 (Feb 2019) ISSN: 1472-8206 [Electronic] England
PMID	29935014 (Publication Type: Case Reports)
Copyright	© 2018 Société Française de Pharmacologie et de Thérapeutique.
Chemical References	Immunologic Factors Natalizumab
Topics	Adult Female Humans Immunologic Factors (administration & dosage, adverse effects) Multiple Sclerosis (drug therapy) Natalizumab (administration & dosage, adverse effects) Papillomavirus Infections (complications, diagnosis) Uterine Cervical Dysplasia (diagnosis, virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!